CA3076150C - Selective p2x3 modulators - Google Patents

Selective p2x3 modulators Download PDF

Info

Publication number
CA3076150C
CA3076150C CA3076150A CA3076150A CA3076150C CA 3076150 C CA3076150 C CA 3076150C CA 3076150 A CA3076150 A CA 3076150A CA 3076150 A CA3076150 A CA 3076150A CA 3076150 C CA3076150 C CA 3076150C
Authority
CA
Canada
Prior art keywords
selective
antagonist
pharmaceutically acceptable
acceptable salt
receptor antagonism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3076150A
Other languages
English (en)
French (fr)
Other versions
CA3076150A1 (en
Inventor
Denis Garceau
Antonios Matzouranis
Roberto Bellini
Kemal Payza
Nathalie Chauret
Susan E. Browne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of CA3076150A1 publication Critical patent/CA3076150A1/en
Application granted granted Critical
Publication of CA3076150C publication Critical patent/CA3076150C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
CA3076150A 2017-09-18 2018-09-14 Selective p2x3 modulators Active CA3076150C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762560077P 2017-09-18 2017-09-18
US62/560,077 2017-09-18
US15/936,316 US10111883B1 (en) 2017-09-18 2018-03-26 Selective P2X3 modulators
US15/936,316 2018-03-26
PCT/IB2018/001513 WO2019064079A2 (en) 2017-09-18 2018-09-14 SELECTIVE MODULATORS OF P2X3

Publications (2)

Publication Number Publication Date
CA3076150A1 CA3076150A1 (en) 2019-04-04
CA3076150C true CA3076150C (en) 2024-01-02

Family

ID=63894683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3076150A Active CA3076150C (en) 2017-09-18 2018-09-14 Selective p2x3 modulators

Country Status (12)

Country Link
US (6) US10111883B1 (enExample)
EP (2) EP4331669A3 (enExample)
JP (1) JP7242681B2 (enExample)
KR (1) KR102713354B1 (enExample)
CN (1) CN111601601A (enExample)
AU (1) AU2018342751B2 (enExample)
CA (1) CA3076150C (enExample)
ES (1) ES2969868T3 (enExample)
IL (2) IL303257A (enExample)
MX (1) MX2020002968A (enExample)
SG (1) SG11202002460QA (enExample)
WO (1) WO2019064079A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164488A (zh) * 2018-10-05 2021-07-23 盐野义制药株式会社 慢性咳嗽治疗用药物
IL282087B2 (en) * 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
DK3880678T3 (da) 2018-11-13 2025-06-10 Glaxosmithkline Intellectual Property No 3 Ltd Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat
KR102797127B1 (ko) * 2018-12-29 2025-04-21 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
CA3131312A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
BR112022015818A2 (pt) 2020-02-14 2022-10-25 Bellus Health Cough Inc Preparação de um antagonista de p2x3
JP2023513373A (ja) * 2020-02-14 2023-03-30 べルス・ヘルス・コフ・インコーポレーテッド Ｐ２ｘ３修飾薬
BR112022021780A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
CN113754654A (zh) * 2020-06-05 2021-12-07 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
WO2022001820A1 (zh) * 2020-06-29 2022-01-06 武汉朗来科技发展有限公司 杂环类化合物的晶型及其制备方法和应用
US20240408131A1 (en) * 2020-07-06 2024-12-12 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
WO2022033567A1 (zh) * 2020-08-13 2022-02-17 上海拓界生物医药科技有限公司 苯并咪唑类衍生物、其制备方法及医药用途
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2022258059A1 (zh) * 2021-06-10 2022-12-15 武汉朗来科技发展有限公司 一种药物组合物、制剂及其制备方法和应用
WO2023020156A1 (zh) * 2021-08-20 2023-02-23 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
WO2024194352A1 (en) 2023-03-23 2024-09-26 Glaxosmithkline Intellectual Property (No.3) Limited Deuterated p2x3 modulators
WO2026022326A1 (en) 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2442797T3 (es) * 2009-11-18 2014-02-13 Neomed Institute Compuestos de benzoimidazol y sus utilizaciones
WO2011116392A2 (en) * 2010-03-19 2011-09-22 University Of Miami Use of p2x purinergic receptor agonists to enhance insulin secretion in pancreatic beta cells
KR102120513B1 (ko) 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CU24411B1 (es) * 2014-12-09 2019-05-03 Bayer Ag Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CA2998742C (en) * 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
CN109996546B (zh) * 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法

Also Published As

Publication number Publication date
US20210069201A1 (en) 2021-03-11
JP7242681B2 (ja) 2023-03-20
IL303257A (en) 2023-07-01
IL273348B2 (en) 2023-11-01
KR102713354B1 (ko) 2024-10-02
SG11202002460QA (en) 2020-04-29
EP3684368B1 (en) 2024-01-03
AU2018342751A1 (en) 2020-04-23
EP4331669A3 (en) 2024-05-01
US20230248736A1 (en) 2023-08-10
US10111883B1 (en) 2018-10-30
EP3684368A4 (en) 2021-05-26
EP4331669A2 (en) 2024-03-06
CN111601601A (zh) 2020-08-28
KR20200092938A (ko) 2020-08-04
IL273348B1 (en) 2023-07-01
US20210322432A1 (en) 2021-10-21
EP3684368A2 (en) 2020-07-29
WO2019064079A2 (en) 2019-04-04
IL273348A (en) 2020-05-31
JP2020534355A (ja) 2020-11-26
MX2020002968A (es) 2020-08-17
EP3684368B8 (en) 2024-02-14
US20200230148A1 (en) 2020-07-23
AU2018342751B2 (en) 2023-06-15
WO2019064079A3 (en) 2019-05-16
CA3076150A1 (en) 2019-04-04
US20220160724A1 (en) 2022-05-26
ES2969868T3 (es) 2024-05-23

Similar Documents

Publication Publication Date Title
AU2018342751B2 (en) Selective P2X3 modulators
JPH07223953A (ja) 中枢神経系疾患治療用薬剤組成物
JP2018522897A (ja) Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
BG66162B1 (bg) Хинуклидинови производни и медицински състави, които ги съдържат
JPH10510554A (ja) 置換されたベンジルアミノピペリジン化合物
JP6599976B2 (ja) 置換ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用
KR102894005B1 (ko) 항바이러스 1,3-다이-옥소-인덴 화합물
AU2021219097A1 (en) P2X3 modulators
US10105373B2 (en) Fused triterpene compounds and uses thereof
RU2382041C2 (ru) Новые сложные эфиры кватернизованного хинуклидина
EP2697219B1 (en) Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
AU2020212596A1 (en) Methods of treating disease with MAGL inhibitors
US10336709B2 (en) Lp-PLA2 inhibitors
CN112714761A (zh) 用作分子伴侣介导的自噬调节剂的化合物
JP2012523416A (ja) セロトニンおよびノルエピネフリン再取り込み阻害剤
CN121159510A (zh) 作为trpa1抑制剂的四唑衍生物
AU610492B2 (en) 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates
JPH032155A (ja) カルバミド酸エステル誘導体
JP2008513380A (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
DK150541B (da) Analogifremgangsmaade til fremstilling af 1-(3-bromisoxazol-5-yl)-2-tert.-butyl-aminoethanol eller farmaceutisk acceptable syreadditionssalte heraf
HK40036201A (en) Selective p2x3 modulators
EP4683713A1 (en) Deuterated p2x3 modulators
CN116514833A (zh) 一种氘代物及其合成方法和医药用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211101

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250422

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260511